Trastuzumab biosimilar (CTTQ Pharma)

曲妥珠单抗生物类似药（正大天晴）

Report date: 2023/08/07 16:15:28

Base Information

Drug NameTrastuzumab biosimilar (CTTQ Pharma)
Drug Alias Name曲妥珠单抗生物仿制药（正大天晴）赛妥TQ-B211
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerStomach NeoplasmsBreast Neoplasms
Global Approved IndicationsStomach NeoplasmsBreast Neoplasms
Approved Indications in ChinaStomach NeoplasmsBreast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2023/07/25
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
Inactive CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Active IndicationsStomach NeoplasmsBreast Neoplasms
Inactive IndicationsMetastatic breast cancer

Other Information

ATC CodeL01XC03
Related LinksN/A